HTRF® cell-based phospho and total-EGFR assay for anti-cancer research
Mutations that lead to an overexpression or hyperactivity of EGFR also known as ErbB1 or HER1, are associated with a number of cancers, such as lung, colorectal, prostate, glioblastoma cancer etc. This makes EGFR a key target for anti-cancer therapies immunoassay.
Cisbio's cell-based homogeneous phospho-EGFR assay kits are designed for the cell-based quantitative detection of phosphorylation on EGFR. One phospho kit allows the measurement of the specific EGFR phosphorylation on Tyr1068, while the other allows all tyrosine phosphorylations to be generically measured. The HTRF® total EGFR assay kit is designed for the quantitative detection of total EGFR, phosphorylated and unphosphorylated, to normalize the phosphorylation status of EGFR with respect to its steady-state level in cells.
The buffers of both HTRF® phospho- and total EGFR assays are compatible, enabling an analysis of the phosphorylated and the total protein populations from one lysate sample.